This study was designed to assess both the quality and cost aspects of various branded and generic formulations of angiotensin receptor blockers, specifically Irbesartan, Losartan Potassium, Olmesartan Medoxomil, Telmisartan, and Valsartan. The collected samples underwent distinct quality evaluations using the methods outlined in different global Pharmacopoeias (British Pharmacopoeia/European Pharmacopoeia, Indian Pharmacopoeia and United States Pharmacopoeia). These drugs were characterized using Fourier-Transform Infrared Spectroscopy and Nuclear Magnetic Resonance techniques, while their quality and concentration were analysed using High Performance Liquid Chromatography. The release profile of the drugs was examined through dissolution testing. Additionally, a cost comparison analysis was carried out by determining the prevailing market prices of the drugs. The evaluated branded and generic angiotensin receptor blockers were found to meet the established standards for impurities, active drug content, and dissolution as set by these Pharmacopoeias, indicating their optimal quality. Notably, the generic drugs exhibited significantly lower costs compared to their branded counterparts. This study confirms that the quality of generic angiotensin receptor blockers is equivalent to that of their branded counterparts. Consequently, these findings support the practicality of utilizing generic drugs as a more economically sustainable and cost-effective approach to managing diseases, especially those of chronic nature.

Delhi Pharmaceutical Science and Research University Mehrauli Badarpur Road Sector 3 Pushp Vihar New Delhi 110017 India

Department of Analytical Chemistry Faculty of Pharmacy in Hradec Králové Charles University Akademika Heyrovského 1203 Hradec Králové 500 05 Czech Republic

Indian Pharmacopoeia Commission Ministry of Health and Family Welfare Government of India Sector 23 Raj Nagar Ghaziabad Uttar Pradesh 201002 India

See more in PubMed

Aivalli P.K., et al. Perceptions of the quality of generic medicines: implications for trust in public services within the local health system in Tumkur, India. BMJ Glob. Health. 2018;2(Suppl 3):e000644. PubMed PMC

Al-Makki A, DiPette D, Whelton PK et., al, Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary. Hypertension. 2022 Jan;79(1):293-301. doi: 10.1161/HYPERTENSIONAHA.121.18192. Epub 2021 Nov 15. PMID: 34775787; PMCID: PMC8654104. PubMed PMC

Anand O., et al. Dissolution Testing for Generic Drugs: An FDA Perspective. AAPS J. 2011;13(3) doi: 10.1208/s12248-011-9272-y. PubMed DOI PMC

Andrew C., et al. Evaluating pharmaceuticals for health policy in low and middle income country settings. Wiley Online Library. 2004 doi: 10.1002/9780470994719.ch14. DOI

Dc S. Trends of generic substitution in community pharmacies. Pharm World Sci. 1999;260(6) doi: 10.1023/a:1008781619011. PubMed DOI

Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension. 2020 Feb;75(2):285-292. doi: 10.1161/HYPERTENSIONAHA.119.14240. Epub 2019 Dec 23. PMID: 31865786; PMCID: PMC10243231. PubMed PMC

Gota V., Patial P. Toward better quality of anticancer generics in India. Indian J. Cancer. 2014;51(3):366. doi: 10.4103/0019-509x.146723. PubMed DOI

Gupta R., et al. Generic Drugs in the United States: Policies to Address Pricing and Competition. Clin. Pharmacol. Ther. 2019;105(2):329–337. doi: 10.1002/cpt.1314. PubMed DOI PMC

Heidari B., Avenatti E., Nasir K. Pharmacotherapy for essential hypertension: A brief review. Methodist DeBakey Cardiovasc J. 2022;18(5):5–16. doi: 10.14797/mdcvj.1175. PubMed DOI PMC

Hill Robert D, Vaidya Prabhakar N. Angiotensin II receptor blockers StatPearls Publishing Jan 2023 Angiotensin II Receptor Blockers (ARB) - StatPearls - NCBI Bookshelf (nih.gov) accessed 09th January 2024. PubMed

https://www.nhs.uk/conditions/high-blood-pressure-hypertension/treatment/accessed December 24, 2022.

Indian Pharmacopoeia Commission. Indian Pharmacopoeia. 9th ed. Sector 23, Raj Nagar Ghaziabad-201002: The Indian Pharmacopoeia Commission, 2022.

Jambhekar S.S., Breen P.J. Drug dissolution: significance of physicochemical properties and physiological conditions. Drug Discov. Today. 2013;18(23–24):1173–1184. doi: 10.1016/j.drudis.2013.08.013. PubMed DOI

Kashyap A., et al. Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India. Expert Rev. Pharmacoecon. Outcomes Res. 2019;20(4):355–361. doi: 10.1080/14737167.2019.1637735. PubMed DOI

Kesselheim A.S. Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease. JAMA. 2008;300(21):2514. doi: 10.1001/jama.2008.758. PubMed DOI PMC

Kingori P., et al. Poor-quality medical products: social and ethical issues in accessing “quality” in global health. BMJ Glob. Health. 2019;4(6):e002151. PubMed PMC

Kovacs S et al. Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries. Sullivan DJ, ed. PLoS ONE 2014; 9(3): e90601. 10.1371/journal.pone.0090601. PubMed PMC

Kumar GR. An analysis of generic medicines in India 2017. Available at: https://www.thehansindia.com/posts/index/Hans/2017-05-09/An-analysis-of-generic-medicines-in-India/298834.

Manzoli L., et al. Generic versus brand-name drugs used in cardiovascular diseases. Eur. J. Epidemiol. 2015;31(4):351–368. doi: 10.1007/s10654-015-0104-8. PubMed DOI PMC

Meredith P.A. Generic Drugs. Drug-Safety. 1996;15:233–242. doi: 10.2165/00002018-199615040-0000. PubMed DOI

Mills K.T., Stefanescu A., He J. The global epidemiology of hypertension. Nat. Rev. Nephrol. 2020;16(4):223–237. doi: 10.1038/s41581-019-0244-2. PubMed DOI PMC

Newton P.N., et al. Impact of poor-quality medicines in the “developing” world. Trends Pharmacol. Sci. 2010;31(3):99–101. doi: 10.1016/j.tips.2009.11.005. PubMed DOI PMC

Oparil S., Acelajado M.C., Bakris G.L., et al. Hypertension. Nat. Rev. Dis. Primers. 2019;4(4):1–48. doi: 10.1038/nrdp.2018.14. PubMed DOI PMC

Patterson J.H., Angiotensin I.I. Receptor Blockers in Heart Failure. Pharmacotherapy. 2003;23(2):173–182. doi: 10.1592/phco.23.2.173.32095. PubMed DOI

Pharmaceuticals & Medical Devices Bureau of India (janaushadhi.gov.in) accessed June 14, 2023.

Rahman M.S., et al. A comprehensive analysis of selected medicines collected from private drug outlets of Dhaka city, Bangladesh in a simple random survey. Sci. Rep. 2022;12(1) doi: 10.1038/s41598-021-04309-1. PubMed DOI PMC

Rajput G., Patel P., Singh D., Asati V., Kurmi B.D. Quality by design assisted high-performance liquid chromatography parameters for simultaneous estimation of simvastatin and fenofibrate. Sep Sci plus. 2022;5:566–578. doi: 10.1002/sscp.202200078. DOI

Shafie A.A., Hassali M.A. Price comparison between innovator and generic medicines sold by community pharmacies in the state of Penang. Malaysia. Journal of Generic Medicines. 2008;6(1):35–42. doi: 10.1057/jgm.2008.25. DOI

Sharma A.K., et al. Impurities Present in Cardiovascular Active Substances and Medicinal Products: A Pharmacopoeial Perspective. Current Chromatography. 2022;9(1) doi: 10.2174/2213240609666220728091253. e280722207051. DOI

Taylor A.A., Helmy S. Journal of Clinical Hypertension n. 2011;Vol 13(9)

Unger T., Borghi C., Charchar F., et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334–1357. doi: 10.1161/hypertensionaha.120.15026. PubMed DOI

United States Pharmacopeial Convention. The United States Pharmacopoeia-National Formulary., 43rd–38th ed. Rockville, Md: United States Pharmacopoeial Convention, 2023. Available at: https://online.uspnf.com/uspnf.

Whelton P.K., Carey R.M., Aronow W.S., et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J. Am. Coll. Cardiol. 2018;71(19):e127–e248. doi: 10.1016/j.jacc.2017.11.006. PubMed DOI

World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. Geneva. 2021. Licence: CC BY-NC-SA 3.0 IGO. PubMed

World Health Organization. Hypertension. World Health Organization. Published March 16, 2023. https://www.who.int/news-room/fact-sheets/detail/hypertension.